CytoMed Therapeutics Ltd
Research CytoMed Therapeutics Ltd (GDTC) on Bullrun: market cap USD 11.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGDTC
- ExchangeNASDAQ
- CountrySingapore
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.83M
- Financial periodQ4 2025
- RevenueUSD 324.39K
- Net income-USD 3.98M
- Free cash flow-USD 4.40M
- Gross margin79.0%
Valuation Snapshot
latest market cap is USD 11.83M.
About CytoMed Therapeutics Ltd
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Frequently asked questions
What is CytoMed Therapeutics Ltd's market cap?
CytoMed Therapeutics Ltd's market capitalization is USD 11.83M.
What does CytoMed Therapeutics Ltd do?
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.